GlassScriptPhysician profile
Mary E Corgan
NPI 1255664280
$4,653.16
in general payments reported to CMS, 2019-2025
21 companies · $949 in 2025
The $949 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,470 · 2022: $1,026 · 2023: $821 · 2024: $387 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,157.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $938.74 | 2021-2024 | Fasenra, Airsupra |
| Abbvie INC. | $650.58 | 2021-2024 | |
| Amgen INC. | $516.53 | 2022-2025 | Evenity, Otezla |
| Novo Nordisk INC | $390.33 | 2021-2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $368.84 | 2021-2025 | Cobenfy, Camzyos |
| Janssen Pharmaceuticals, INC | $260.81 | 2021-2023 | Xarelto |
| Madrigal Pharmaceuticals | $138.45 | 2025 | Rezdiffra |
| Dexcom, INC. | $135.62 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Recor Medical INC | $129.90 | 2025 | Paradise Ultrasound Renal Denervation System |
| Pacira Pharmaceuticals Incorporated | $124.83 | 2025 | Iovera |
| Gilead Sciences, INC. | $123.01 | 2022-2024 | Veklury |
| Grifols USA, LLC | $122.38 | 2023 | Prolastin-C Liquid |
| Daiichi Sankyo INC. | $122.24 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $119.05 | 2023 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $116.36 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $109.79 | 2021 | |
| Lilly USA, LLC | $105.54 | 2022 | |
| Merck Sharp & Dohme LLC | $83.39 | 2022-2023 | Verquvo |
| Pfizer INC. | $61.20 | 2022 | |
| Kestra Medical Technology Services, INC. | $22.37 | 2025 | Assure Wcd |
| Cumberland Pharmaceuticals, INC. | $13.20 | 2023 | Caldolor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Corgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.